In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, stab-free way to treat diabetes and obesity.

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial results.

A recent medical trial could help deliver the first daily weight loss pill capable of cutting down obesity as effectively as Ozempic.

Competition is mounting in the weight loss sector as giants like Eli Lilly, Roche, Novo Nordisk and Pfizer explore oral weight loss drugs that could be a boon to people wanting a needle-free ...

There’s always a lot riding on these presentations, called readouts. But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught.

When taken for 40 weeks for type 2 diabetes, orforglipron resulted in an average loss of 16 pounds, or about 7.9% of the patient's body weight, at the highest dose. HealthDay News — A new pill ...

Eli Lilly's new oral weight loss pill, orforglipron, shows promise in Phase 3 trials, offering a convenient alternative to injectable GLP-1 drugs like Ozempic and Mounjaro. With significant weight ...

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial results.

The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes patients lower blood sugar—and ...

FRIDAY, April 18, 2025 (HealthDay News) — A new pill designed to help with weight loss and blood sugar control is showing promise in early studies. Eli Lilly said its experimental drug ...